Table 2.
Disproportionality analysis by drug
| Drug | ROR | 95% CI (p<0.001) | % GBS over other events |
| Avelumab | 29.854 | 14.8 to 58.9 | 0.57 |
| Atezolizumab | 17.075 | 12.5 to 23.1 | 0.32 |
| Ipilimumab | 16.084 | 12.4 to 20.8 | 0.30 |
| Pembrolizumab | 11.977 | 9.4 to 15.1 | 0.22 |
| Nivolumab | 8.218 | 6.3 to 10.6 | 0.15 |
.GBS, Guillain-Barré syndrome; ROR, reporting OR.